Bros. Advisors Lp Baker Sells 11,204 Shares of Genomic Health, Inc. (GHDX) Stock

Genomic Health, Inc. (NASDAQ:GHDX) Director Bros. Advisors Lp Baker sold 11,204 shares of Genomic Health stock in a transaction that occurred on Friday, April 12th. The stock was sold at an average price of $65.32, for a total value of $731,845.28. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Bros. Advisors Lp Baker also recently made the following trade(s):

  • On Monday, April 8th, Bros. Advisors Lp Baker sold 22,648 shares of Genomic Health stock. The shares were sold at an average price of $67.90, for a total value of $1,537,799.20.
  • On Wednesday, April 10th, Bros. Advisors Lp Baker sold 168,253 shares of Genomic Health stock. The shares were sold at an average price of $68.47, for a total value of $11,520,282.91.
  • On Wednesday, April 3rd, Bros. Advisors Lp Baker sold 97,269 shares of Genomic Health stock. The shares were sold at an average price of $68.90, for a total value of $6,701,834.10.
  • On Friday, April 5th, Bros. Advisors Lp Baker sold 255,970 shares of Genomic Health stock. The shares were sold at an average price of $68.12, for a total value of $17,436,676.40.
  • On Thursday, March 21st, Bros. Advisors Lp Baker sold 56,651 shares of Genomic Health stock. The shares were sold at an average price of $74.71, for a total value of $4,232,396.21.
  • On Tuesday, March 19th, Bros. Advisors Lp Baker sold 270,006 shares of Genomic Health stock. The shares were sold at an average price of $74.45, for a total value of $20,101,946.70.
  • On Thursday, March 14th, Bros. Advisors Lp Baker sold 65,094 shares of Genomic Health stock. The shares were sold at an average price of $76.49, for a total value of $4,979,040.06.
  • On Thursday, March 7th, Bros. Advisors Lp Baker sold 2,000 shares of Genomic Health stock. The shares were sold at an average price of $73.72, for a total value of $147,440.00.
  • On Monday, March 11th, Bros. Advisors Lp Baker sold 73,735 shares of Genomic Health stock. The stock was sold at an average price of $74.52, for a total value of $5,494,732.20.
  • On Tuesday, March 5th, Bros. Advisors Lp Baker sold 117,387 shares of Genomic Health stock. The stock was sold at an average price of $77.02, for a total value of $9,041,146.74.

GHDX opened at $67.55 on Friday. Genomic Health, Inc. has a 52-week low of $33.12 and a 52-week high of $92.18. The stock has a market cap of $2.50 billion, a P/E ratio of 64.33 and a beta of 0.89.

Genomic Health (NASDAQ:GHDX) last released its earnings results on Wednesday, February 20th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.30 by $0.02. The business had revenue of $104.56 million for the quarter, compared to analyst estimates of $101.55 million. Genomic Health had a return on equity of 16.86% and a net margin of 6.52%. Genomic Health’s revenue was up 22.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.05 earnings per share. On average, analysts expect that Genomic Health, Inc. will post 1.49 EPS for the current fiscal year.

A number of research firms have issued reports on GHDX. Zacks Investment Research cut Genomic Health from a “buy” rating to a “hold” rating in a research note on Tuesday, April 23rd. BidaskClub cut Genomic Health from a “buy” rating to a “hold” rating in a research report on Saturday, March 30th. ValuEngine cut Genomic Health from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, March 5th. Piper Jaffray Companies upped their price objective on Genomic Health to $86.00 and gave the stock a “neutral” rating in a research report on Thursday, February 21st. Finally, Needham & Company LLC reaffirmed a “strong-buy” rating and set a $97.00 price objective (up from $86.00) on shares of Genomic Health in a research report on Thursday, February 21st. Nine research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $67.29.

Large investors have recently added to or reduced their stakes in the business. Pearl River Capital LLC bought a new stake in Genomic Health in the first quarter valued at approximately $70,000. Royce & Associates LP raised its stake in Genomic Health by 22.8% in the fourth quarter. Royce & Associates LP now owns 1,473 shares of the medical research company’s stock valued at $95,000 after buying an additional 273 shares during the period. Advisor Group Inc. raised its stake in Genomic Health by 34.9% in the fourth quarter. Advisor Group Inc. now owns 1,995 shares of the medical research company’s stock valued at $129,000 after buying an additional 516 shares during the period. Pacer Advisors Inc. bought a new position in shares of Genomic Health during the third quarter worth approximately $171,000. Finally, Quantamental Technologies LLC bought a new position in shares of Genomic Health during the fourth quarter worth approximately $180,000. Hedge funds and other institutional investors own 90.67% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/05/05/insider-selling-genomic-health-inc-ghdx-director-sells-11204-shares-of-stock.html.

About Genomic Health

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Featured Story: What is a closed-end mutual fund (CEF)?

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.